June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Autologous Serum Tears for Treatment of Dry Eye Syndrome in Graft Versus Host Disease
Author Affiliations & Notes
  • Ryan Fante
    Ophthalmology and Visual Sciences, UM Kellogg Eye Center, Ann Arbor, MI
  • Roni Shtein
    Ophthalmology and Visual Sciences, UM Kellogg Eye Center, Ann Arbor, MI
  • Shahzad Mian
    Ophthalmology and Visual Sciences, UM Kellogg Eye Center, Ann Arbor, MI
  • Munira Hussain
    Ophthalmology and Visual Sciences, UM Kellogg Eye Center, Ann Arbor, MI
  • Footnotes
    Commercial Relationships Ryan Fante, None; Roni Shtein, None; Shahzad Mian, None; Munira Hussain, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 977. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ryan Fante, Roni Shtein, Shahzad Mian, Munira Hussain; Autologous Serum Tears for Treatment of Dry Eye Syndrome in Graft Versus Host Disease. Invest. Ophthalmol. Vis. Sci. 2013;54(15):977.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the effectiveness of autologous serum tears for treatment of severe dry eye syndrome (DES) in patients with Graft Versus Host Disease (GVHD).

Methods: Retrospective review of 30 eyes of 15 patients with GVHD and severe DES was performed at baseline and after initiating treatment with autologous serum tears. Severity of ocular surface disease was evaluated using the Schirmer test, fluorescein staining and Ocular Surface Disease Index (OSDI). Paired t-tests were performed to compare baseline assessment to post-treatment scores.

Results: The study population included 15 total patients, 7 female and 8 male; the average age was 54 years (s.d =9, range 40-67). Follow-up duration averaged 11 months (range 1-40), and 60% were concurrently using the Prosthetic Replacement of Ocular Surface Environment (PROSE) lens. Patients had an average of 3 blood draws (s.d.=2, range: 1-8) for serum tears in this time period. There was a statistically-significant improvement in OSDI scores at 1 month and final time-points compared to pre-treatment (baseline: 59.7 +/- 27.0; 1 month: 42.5 +/- 22.1, p=0.03; 3 month: 49.5 +/-37.0, p=0.07; final: 40.1 +/- 26.7, p=<0.001). Schirmer score significantly improved at 1 month compared to pre-treatment (baseline: 2.6 +/- 3.1; 1 month: 5.0 +/-4.0, p=0.01). Schirmer scores did not significantly differ at 3 month and final time points (3 month: 4.7 +/-5.9; final: 4.6 +/- 6.5). Fluorescein staining score did not significantly differ from pre-treatment at any time points (baseline: 2.3 +/- 1.1; 1 month: 2.5 +/- 1.5; 3 month: 1.2 +/- 1.5; final: 1.9 +/- 1.3).

Conclusions: Autologous serum tears are an effective treatment for DES in patients with GVHD. Additional studies are needed to compare the effectiveness of autologous serum tears to other treatments for patients with severe DES from GVHD.

Keywords: 486 cornea: tears/tear film/dry eye • 482 cornea: epithelium • 479 cornea: clinical science  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×